Victor Grann

Victor Grann

Victor Grann

Clinical Professor of Emeritus
Medicine, Epidemiology and Health Policy and Management

Office/Address:

722 West 168th Street/Rm 734
New York NY USA 10032
Phone:
212-305-9529
Fax:
212-305-9413
Website address: Email:

Biography

Dr. Victor Grann's research and teaching interests include quality of life, preference ratings, and decision analysis of health outcomes related to genetic mutations in breast and ovarian cancer and cancer prevention. He is the principal investigator for the STAR trial at Columbia and has done several studies examining the barriers to minority participation in the trial. Dr. Grann also serves as the facility director of the recruitment and retention core for the Herbert Irving Comprehensive Cancer Center, which develops outreach programs for the underserved community surrounding the Columbia University Medical Center.

Topics

Education

MPH, 1997, Mailman School of Public Health
MD, 1962, New York Medical College
BA, 1955, Yale University

Other Affiliations

American Society of Clinical Oncology
American Cancer Society
Carnegie Council of Ethics in International Affairs

Areas of Expertise

Outcomes Research, Risk Assessment and Communication, Cancer, Cancer Breast, Cancer Screening, Community Programs and Outreach, Disparities / Inequalities in Health, Minority Health, Social / Cultural Issues, Social Epidemiology, Genetic Susceptibility, Genetics, Ethics, Healthcare Policy

Select Urban Health Activities

Research Recruitment and Minority Outreach Shared Resource of the HICCC: The Recruitment and Minority Outreach Shared Resource at the cancer center's goal is to educate our community surrounding Columbia especially minorities about the results and advantages of clinical research.

Select Publications

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI A decision analysis of prophylactic mastectomy and oophorectomy in BRCA1 or BRCA2 positive patients Journal of Clinical Oncology 16 979-85. 1998
Grann VR, Bowman N, Joseph C, et al. Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer 113(4) 854-60 2008
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2 Journal Clinical Oncology 17 494-500. 1999
Grann VR, Jacobson JS, Sundararajan V, et al The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations Cancer Journal Scientific Americian 5 283-92. 1999
Grann VR, Jacobson JS, Whang W, et al. Prevention with tamoxifen or other hormones vs. prophylactic surgery in BRCA1/2 positive women: a decision analysis Cancer Journal Scientific American 6 13-20. 2000
Hershman D, Sundararajan V, Jacobson JS, Neugut AI, Grann VR Benefits of tamoxifen according to risk for the prevention of invasive breast cancer: a decision analysis Journal Clinical Oncology 20 9-16 2002
Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI Efficacy of prevention strategies on survival and quality–adjusted survival of women with BRCA1/2 mutations: an updated decision analysis Journal Clinical Oncology 20 :2520-2529 2002
Grann VR, Neugut AI Lung cancer screening at any price? JAMA 289 357-8 2003
Grann VR, Jacobson JS Health insurance and cancer survival Archives Internal Medicine 163 2123-4 2003
Grann VR, Ziv E, Joseph CK, et al. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol. 143(2):288-93. 143(2) 288-93 2008;
Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103(11):2241-51. 103(11) 2241-51 2005

Back to Top